Streetbeat News

Revenues

BCH

Bitcoin Cash (BCH) saw a 6.8% increase to $565.51 amid overall strength in altcoins and Bitcoin, which surpassed $70,000. The rise in Bitcoin and altcoins is attributed to the approval of spot Bitcoin ETFs in January and recent significant investments in Bitcoin spot ETFs, including a $323 million inflow into BlackRock's iShares Bitcoin Trust. This reflects growing confidence in Bitcoin, supported by BlackRock CEO Larry Fink's positive outlook.

Portfolio Pulse from Henry Khederian

March 28, 2024 | 5:03 pm

MDB

In the latest quarter, 26 analysts provided mixed ratings for MongoDB (NASDAQ:MDB), with a shift towards more bullish perspectives compared to previous months. The average 12-month price target is now $447.46, down from $467.37, reflecting a 4.26% decrease. Analyst actions include a range of adjustments to ratings and price targets, indicating varied expectations for MongoDB's future performance. MongoDB's financial performance shows strong growth and profitability, with a notable revenue growth rate of 26.76% and a market capitalization above the industry average.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 5:01 pm

FC

Franklin Covey (NYSE:FC) received mixed analyst ratings with a shift towards a somewhat bullish outlook, despite a decrease in the average 12-month price target from $77.50 to $62.5, indicating a 19.35% decrease. Analysts from Northland Capital Markets and Barrington Research adjusted their price targets and maintained an 'Outperform' rating. Franklin Covey's financial performance shows a negative revenue trend with a -1.4% growth over 3 months, yet it outperforms industry averages in net margin, ROE, and ROA, with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 5:01 pm

IREN

Analysts have diverse opinions on Iris Energy (NASDAQ:IREN), with recent ratings ranging from bullish to somewhat bullish. The average 12-month price target is $9.62, marking a 10.96% increase from the previous target. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting dynamic market conditions. Iris Energy, a Bitcoin mining company powered by renewable energy, shows positive financial indicators such as a 205.69% revenue growth rate and strong net margin, despite a reduced market capitalization.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 5:00 pm

WULF

In the past three months, TeraWulf (NASDAQ:WULF) received mixed analyst ratings, with a recent shift towards a somewhat bullish outlook. The average 12-month price target is $3.88, reflecting a 3.47% increase from the previous target. Analysts from Cantor Fitzgerald and Compass Point have adjusted their ratings and price targets, indicating a nuanced view of TeraWulf's market position and financial performance. TeraWulf, a digital asset technology company, focuses on sustainable bitcoin mining in the U.S., showing significant revenue growth and operational challenges.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 5:00 pm

CVS

ELV

NVO

A study reveals Novo Nordisk's diabetes drug Ozempic could be produced for under $5, contrasting its $1,000 U.S. price tag. The study, involving Yale University and others, highlights the affordability issue in diabetes care. Major insurers like CVS Health and Elevance Health announced coverage for another Novo Nordisk drug, Wegovy, for certain Medicare patients. Novo Nordisk defends its pricing, citing significant R&D investments and efforts to ensure patient access through rebates and discounts.

Portfolio Pulse from Vandana Singh

March 28, 2024 | 4:54 pm

AXP

Analysts have updated their ratings on American Express (NYSE:AXP), showing a mix of perspectives with an average 12-month price target of $209.6, indicating a 5.93% increase from the previous target. The company's financials reveal strong performance, including a revenue growth rate of 13.27% and a net margin of 12.06%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 4:01 pm

MOH

Recent analyst evaluations of Molina Healthcare (NYSE:MOH) show diverse opinions, with the latest average 12-month price target being $433.67, an 8.69% increase from the previous target. Analysts' ratings range from 'Underperform' to 'Overweight', reflecting varied expectations for the company's performance. Molina Healthcare's financial overview indicates a strong market position with notable revenue growth, net margin, ROE, and ROA, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 4:01 pm

HRMY

Harmony Biosciences (NASDAQ:HRMY) was analyzed by 8 financial analysts, showing a mix of bullish to bearish sentiments. Recent ratings indicate a shift towards a more cautious outlook, with the average 12-month price target set at $42.62, reflecting an 11.42% increase from the previous target. Analyst actions vary, with some maintaining their ratings while others adjust their price targets. Harmony Biosciences, a commercial-stage pharmaceutical company, has shown strong financial health with a notable revenue growth rate of 31.26%, a net margin of 15.8%, and an exceptional ROE of 5.61%.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 4:00 pm

BLDR

Builders FirstSource (NYSE:BLDR) received diverse analyst ratings over the past quarter, with a shift towards more neutral positions in the last 30 days. The average 12-month price target for BLDR is now $215.43, marking a 12.79% increase from the previous target of $191.00. Analysts from firms like DA Davidson, Barclays, and RBC Capital have updated their ratings and price targets, reflecting changes in market conditions and company performance. Despite a negative revenue trend and challenges in maintaining profitability, BLDR's strong ROE and ROA indicate effective capital utilization. The company's market capitalization and debt management are also highlighted as strengths.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 4:00 pm